▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1647 by analyst upside · 2026-06-27
GHRS
GH Research PLC
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+40.0%
implied upside to consensus target
Current Price $28.22
Consensus Target $39.5
Bull Target $65.0
Bear Target $32.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
5
Hold
0
Sell
0
52-Week Low $11.32
52-Week High $28.32
YTD Return +113.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -14.1x
EPS (TTM) $-1.01
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.32
52-Week High $28.32
Current Price $28.22
Bear Target $32.0
Bull Target $65.0
● Now $28.22 ● Target $39.5
TRADING DATA
Avg Volume 245K
YTD Return +113.1%
Analyst Count 8
Consensus Buy
Upside to Target +40.0%
Last Updated 2026-06-27

ANALYST SUMMARY

GH Research PLC (GHRS) is currently trading at $28.22 with a Wall Street consensus price target of $39.5, implying potential upside of 40.0% over the next 12 months. 8 analysts currently cover GHRS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $65.0, while the most cautious has a target of $32.0.

GHRS operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 113.1% year-to-date and is currently trading near the upper end of its 52-week range of $11.32 – $28.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
ANIP +33.4%
ANI Pharmaceuticals, Inc.
$2B · P/E 21.3x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GHRS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-19 31% win rate (48 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-05-15 40% win rate (10 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-15 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-03-06 Building track record
Needham — Reiterated
Buy → Buy 2026-03-06 20% win rate (5 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-01-23 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-01-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
17/30
Consensus clarity
7/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →